No Data
Strong performance of healthcare stocks, Hang Seng Healthcare Index rose by 1.34%. JingTai Technology (02228) rose by 21.84%.
Golden Guard Financial News | Pharmaceutical stocks show strong performance, with the Hang Seng Healthcare Index rising by 1.34%. Among them, Crystal Tai Technology quantumph-p (02228) rose by 21.84%, Yimingang Science (01541) rose by 9.94%, Zai Lab (09688) rose by 9.64%, Lifetech Sci (01302) rose by 5.22%, Lai Kai Medical (02105) rose by 5.52%, Tigermed (03347) rose by 5.36%. China Thai International stated that since October, there has been differentiation in the performance of pharmaceutical industry stocks. Among the components of the Hang Seng Healthcare Index, the stock prices have risen due to the previous stimulus from interest rate cuts.
Lai Kai Medicine - B [02105] is now trading at 9.59 Hong Kong dollars, with a 10.23% increase in the price.
As of 09:40, Kaiyao-B [02105] reported 9.59 Hong Kong dollars, up 0.89 Hong Kong dollars or 10.23% from yesterday's closing price of 8.7 Hong Kong dollars, with a turnover of 9.1251 million Hong Kong dollars. The highest price today is 9.59 Hong Kong dollars, the lowest price is 8.87 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 7.42 Hong Kong dollars, the 50-day average price is 5.55 Hong Kong dollars, the current P/E ratio is -4.70 times, and the 14-day relative strength index is 69.04.
Laekna Begins Phase I Clinical Trial for Obesity Treatment
[Hong Kong Stock Connect] Lai Kai Medicine (02105) surged 33.06% in the afternoon. The first domestic multi-disciplinary diagnosis and treatment guidelines for obesity were released. Significant progress has been made in clinical treatment of obesity rece
King's Financial News | In the afternoon, the short-term rapid rise of Lai Kai Medical (02105), as of the press release, increased by 33.06%, to 8.21 Hong Kong dollars, with a turnover of 0.128 billion Hong Kong dollars. On the news front, on October 17, the National Health Commission issued the 'Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)'. This is the first authoritative guidelines for the diagnosis and treatment of obesity in multiple disciplines in China, which is of great significance in standardizing the clinical diagnosis and treatment of obesity in medical institutions. In recent years, the prevalence of overweight and obese populations in China has been continuously increasing. As an independent disease in chronic diseases and an important one among various chronic diseases.
Biomedical stocks are performing strongly. Lai Kai Medicine (02105) rose by 26.26%, institutions pointed out that the sector's valuation has reached a historical low, still with further room for recovery.
Golden Finance News | Biomedical stocks are strong, with LaiKai Pharmaceutical (02105) up 26.26%, AmyMed Vaccine (06660) up 19.76%, YimingAngke (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, Hutchmed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%. Bocom Intl stated that the tenth batch of National Drug Centralized Procurement Volume Document shows the highest historical threshold for this round of national procurement, the highest proportion of injections in history, and expects the competition to be exceptionally fierce, but for
Kai (2105.HK) LAE102 Phase I clinical trial for obesity has made significant progress. Subcutaneous injection-related research has been initiated.
- The subcutaneous injection part of the single dose escalation study has been initiated - Over half of the intravenous infusion queue has completed dosing, and early signs of target binding and expected PD biomarker changes have been observed in the low-dose group - It is expected to complete the LAE102 single dose escalation study by the end of 2024. On October 16, 2024, Laike Pharmaceuticals (2105.HK) announced that its independently developed LAE102 (ActRIIA monoclonal antibody) has made significant progress in Phase I clinical trials conducted in China for overweight/obese individuals: subcutaneous injection in the single dose escalation (SAD) study.
No Data
No Data